The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells

Key Points

• This research aims to evaluate the anti-tumor efficacy of MIRTX compared to miR-29b-3p in pancreatic cancer cells.
• Comparative analysis of the effects of MIRTX and miR-29b-3p on pancreatic cancer cells.
• Assessment of cell viability and proliferation in response to treatment.
• Evaluation of apoptotic pathways activated by MIRTX and miR-29b-3p.
• MIRTX demonstrated significantly greater anti-tumor activity compared to miR-29b-3p.
• Cells treated with MIRTX showed reduced viability and increased apoptosis.
• MIRTX triggered distinct molecular pathways compared to miR-29b-3p.